Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
Yair Herishanu, Irit Avivi, Shai Levi, Gabi Shefer, Yotam Bronstein, M. Morales, Tomer Ziv, Lydia Scarfò, Chava Perry, Paolo Ghia
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Chronic lymphocytic leukemiaMedicineVaccination2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyVirologyImmunologyPersistence (discontinuity)LeukemiaInternal medicineGeotechnical engineeringEngineeringInfectious disease (medical specialty)DiseaseOutbreakChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders